CNBC quantifies the GLP-1 hit to US restaurant dinner traffic
A restaurant industry analyst says dinner traffic is down about 6% among regular GLP-1 users, cutting overall dinner sales roughly 0.4% — and chains are rebuilding menus around protein, fiber and smaller portions. [1]
US restaurants are starting to put hard numbers on how GLP-1 medications are changing mealtime. Dinner traffic has fallen about 6% among consumers who take the drugs regularly, which works out to roughly a 0.4% decline in overall restaurant sales during dinner hours, according to Dana Baggett, executive director of restaurant client strategy at RRD, which works with more than 200 restaurant brands [1].
The pullback is not spread evenly across the day. Lunch has not been hit so far, Baggett said, while breakfast has taken a hit — particularly from higher-income GLP-1 users, who make up a larger share of current patients. In practice that means fewer sugary coffee drinks and doughnuts, though items like Starbucks' protein cold foam could bring some of those customers back [1]. Dinner, especially at fast-food restaurants, has absorbed the most damage so far [1].
The broader eating shift
About one in eight US adults is currently taking a GLP-1 drug such as Ozempic (semaglutide) or Zepbound (tirzepatide), according to a KFF Health Tracking Poll conducted Oct. 27 to Nov. 2; 18% of respondents said they have taken one at some point [1]. J.P. Morgan estimates more than 30 million Americans could be on a GLP-1 treatment by 2030, up from 10 million in 2026 [1].
The drugs slow digestion, suppress appetite and increase satiety [1]. KPMG data cited by CNBC found adults who use GLP-1s consume 21% fewer calories and spend nearly a third less on groceries on average [1]. About half of users report eating fewer calories, according to UBS Evidence Lab [1]. Among those who report cutting calories, about 70% said they are snacking less and about 60% said they are dining out less often, based on an EY-Parthenon survey conducted last spring [1]. Roughly 45% of survey respondents who are eating and drinking less said they are drinking less alcohol [1].
Estimates vary widely on the size of the restaurant effect. Bernstein surveys indicate restaurant visit frequency among GLP-1 users can fall by as much as 45%, depending on the food category and the occasion, analyst Danilo Gargiulo wrote in a March research note [1]. That is a much larger figure than RRD's 6% dinner traffic number, and the sources measure different things — Bernstein looked at visit frequency by category and occasion, while RRD tracked dinner traffic among consistent users [1].
Why it matters for patients
The practical upshot is that menus are being rewritten with GLP-1 users in mind. Don K. Johnson, principal of strategy and execution at EY-Parthenon, told CNBC that companies are labeling items "GLP-1 friendly," shrinking serving sizes, emphasizing protein and, in beverages, addressing hydration [1].
Those changes track with the nutrition concerns that come with eating less. Because GLP-1 drugs lower calorie intake, every calorie matters more; protein intake is more important to help prevent muscle loss, fiber supports gut health and digestion, and staying hydrated helps blunt side effects such as nausea and headaches, CNBC reported [1].
Real examples are already on shelves and menus. Chipotle launched grab-and-go protein cups in December [1]. Olive Garden, owned by Darden Restaurants, released a Lighter Portions menu last year with downsized entrees at a lower price; CEO Rick Cardenas said it was meant to give all customers more options but "just so happens to benefit the consumers that might want smaller portions that are on GLP-1 medications" [1]. Nestlé's Vital Pursuit frozen line, launched in 2024, saw sales rise after the packaging prominently added a "GLP-1 friendly" callout [1]. J&J Snack Foods has added protein to its soft pretzels in a smaller portion size [1].
A caution: "GLP-1 friendly" is a marketing label, not a regulated nutrition standard, and the sources do not describe any agency defining or verifying it.
What happens next
Novo Nordisk launched its Wegovy pill (oral semaglutide) in January, and Eli Lilly is preparing to roll out its own oral drug this year [1]. J.P. Morgan estimates broader use could wipe out $30 billion to $55 billion in annual food and beverage industry sales as soon as 2030 [1].
Some chains say they see no effect yet. Domino's Pizza CEO Russell Weiner told analysts last month the company hasn't seen GLP-1 drugs affect sales, saying dinner "for us, is a sharing occasion" [1]. McDonald's CEO Chris Kempczinski said the chain is testing items shaped by "less snacking" and "less sugary drinks" among users [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.